Blood Preparation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Whole Blood, Blood Components, Blood Derivatives), By Type (Platelet Aggregation Inhibitors, Fibrinolytics, Anticoagulants), By Application (Thrombocytosis, Pulmonary Embolism, Renal Impairment, Angina Blood Vessel Complications, Others) Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 44.14 Billion
CAGR (2026-2031)	6.49%
Fastest Growing Segment	Thrombocytosis
Largest Market	North America
Market Size (2031)	USD 64.37 Billion

Market Overview

The Global Blood Preparation Market will grow from USD 44.14 Billion in 2025 to USD 64.37 Billion by 2031 at a 6.49% CAGR. Blood preparation encompasses the systematic collection, screening, and fractionation of whole blood into therapeutic components, such as red blood cells, platelets, and plasma, for medical application. The market is primarily supported by the rising prevalence of chronic hematological disorders and the escalating demand for transfusions during complex surgeries and trauma cases. Furthermore, the expanding geriatric population acts as a distinct driver, as this demographic frequently necessitates long-term blood-based therapies for disease management, thereby ensuring sustained demand for preparation technologies and consumables.

However, the market faces a significant impediment regarding supply chain stability and persistent inventory shortages which hamper the timely availability of essential products. This challenge is exacerbated by fluctuating donor retention rates and logistical constraints in maintaining adequate stockpiles. According to the Association for the Advancement of Blood & Biotherapies, in December 2025, sourcing O-negative and B-negative blood to meet spot usage required forty-eight hours or longer due to supply constraints. Such delays highlight the operational fragility that could restrict broader market expansion.

Key Market Drivers

The increasing adoption of novel oral anticoagulants (NOACs) and advanced therapies, particularly plasma-derived medicinal products, acts as a primary catalyst for the blood preparation sector. As healthcare providers shift towards targeted treatments for immune deficiencies and autoimmune neuropathies, the requirement for precise fractionation and component separation technologies has intensified to ensure product purity and efficacy. This demand surge is evident in the financial performance of major industry players scaling operations to meet global therapeutic needs. According to Grifols, February 2025, in the 'Fourth Quarter and Full Year 2024 Results', the company's immunoglobulin franchise experienced robust expansion, recording a full-year growth of 15.3% driven by strong global underlying demand. This trend underscores the critical role of advanced blood preparation techniques in manufacturing high-value therapeutic proteins that define modern hematology.

Simultaneously, the rising volume of emergency trauma cases and the evolution of prehospital care protocols are propelling market momentum. Healthcare systems are increasingly integrating whole blood and component therapies directly into emergency response vehicles to improve survival rates for trauma victims with severe hemorrhage. This shift necessitates expanded localized processing capabilities and specialized storage solutions outside traditional hospital settings. According to America's Blood Centers, May 2025, in the 'A Vital Resource' report, the number of community blood centers providing blood products for specialized prehospital programs nearly doubled to 34 between 2022 and 2024. This operational expansion serves to counterbalance the pressures of chronic disease management; for instance, according to the American Cancer Society, in 2025, approximately 2,041,910 new cancer cases were projected to occur in the United States, maintaining a consistently high baseline demand for transfusions alongside emergency utilization.

Download Free Sample Report

Key Market Challenges

Supply chain instability and persistent inventory shortages create a volatile environment for the blood preparation market. When collection centers cannot maintain adequate stock, the utilization of preparation technologies and consumables declines because there is insufficient raw material to process. This operational bottleneck restricts the ability of market players to scale their processing capabilities and fulfill hospital orders efficiently. The unpredictability of donor turnout leads to operational inefficiencies, forcing facilities to operate below capacity while still incurring fixed maintenance costs for equipment and labor.

These shortages directly reduce the volume of blood products available for therapeutic application, stalling revenue recognition for processing entities. The inability to secure a consistent inflow of whole blood means that demand from healthcare providers remains unmet, disrupting the market ecosystem. According to the American Red Cross, in August 2024, the national blood supply fell by more than 25 percent over a single month, creating a critical inventory gap. Such significant deficits hinder the consistent application of screening and fractionation processes, thereby limiting the overall market growth potential during periods of scarcity.

Key Market Trends

The Integration of Pathogen Reduction and Inactivation Technologies is fundamentally altering market dynamics by prioritizing transfusion safety and inventory longevity. Blood centers are rapidly deploying systems that utilize photochemical processes to neutralize pathogens in platelets and plasma, effectively minimizing the risk of bacterial contamination and transfusion-transmitted infections without relying solely on detection methods. This technological shift not only enhances patient safety profiles but also extends the viable shelf life of components, directly addressing critical wastage challenges in the supply chain. According to Cerus Corporation, November 2025, in the 'Third Quarter 2025 Financial Results', the company reported a 15% year-over-year increase in product revenue, a surge attributed to the robust global demand for its pathogen-reduced platelet and fibrinogen systems.

The Adoption of Automated Blood Component Separation Systems is optimizing processing workflows to meet the requirement for high-yield therapeutic products. Facilities are increasingly replacing manual separation methods with closed-loop automated platforms that efficiently fractionate whole blood or collect specific components via apheresis, thereby improving operational throughput and product consistency. This transition supports scalable production while reducing labor dependencies and processing errors, allowing centers to maximize the utility of every donation. According to Haemonetics Corporation, November 2025, in the 'Q2 Fiscal 2026 Results' release, the company’s Plasma segment achieved an organic revenue growth of 19% (excluding transitional supply agreements), reflecting the accelerated industry uptake of next-generation automated collection and separation devices.

Segmental Insights

The Thrombocytosis segment represents the fastest-growing application within the Global Blood Preparation Market, primarily driven by the rising incidence of myeloproliferative neoplasms and chronic conditions that induce elevated platelet counts. This expansion is substantially supported by improvements in diagnostic capabilities, which facilitate the early detection of hematological abnormalities and subsequently expand the patient pool requiring therapeutic intervention. Furthermore, the increasing reliance on specialized blood derivatives and anticoagulation therapies to manage the associated clotting risks fuels this upward trend. As healthcare providers intensify their focus on preventing thrombotic complications, the demand for targeted blood preparation solutions continues to escalate.

Regional Insights

North America maintains a leading position in the global blood preparation market due to the high prevalence of chronic blood disorders requiring regular transfusion therapies. This regional dominance is supported by a well-established healthcare infrastructure that facilitates consistent blood collection and processing. Additionally, the presence of major industry players within the United States and Canada drives continuous product development and commercialization. The market is further bolstered by favorable initiatives from regulatory bodies, such as the U.S. Food and Drug Administration, which ensure high safety standards and timely approval of new blood preparation solutions.

Recent Developments

• In January 2025, Fresenius Kabi received FDA 510(k) clearance for its Adaptive Nomogram, a new intelligent algorithm designed to optimize plasma collection efficiency for the Aurora Xi Plasmapheresis System. This technology enabled personalized plasma collection targets based on individual donor characteristics, which was clinically shown to increase the average plasma yield by approximately 11.5% while strictly maintaining donor safety standards. The company announced that Takeda's BioLife Plasma donation centers would be the first to implement this innovation operationally. This regulatory clearance represented a significant technical advancement in addressing the growing global demand for plasma-derived therapies by sustainably improving collection volumes per donation event.
• In December 2024, Haemonetics Corporation entered into a definitive agreement to sell its whole blood assets to GVS, a global manufacturer of filter solutions. The transaction involved a total potential cash consideration of up to $67.1 million, including an upfront payment and contingent earn-outs. Under the terms of the agreement, the buyer acquired the company's complete portfolio of proprietary whole blood collection, processing, and filtration solutions, along with manufacturing facilities located in California and Mexico. This strategic divestiture allowed the company to concentrate its resources on its automated apheresis solutions for plasma and platelet collection while streamlining its operational footprint.
• In October 2024, Terumo Blood and Cell Technologies launched the Reveos Automated Blood Processing System in the United States. This innovative platform was the first whole blood automation device introduced in the U.S. market capable of processing whole blood into platelets, plasma, and red blood cell concentrates during a single centrifugation cycle. The system was designed to enhance operational efficiency for blood centers by significantly reducing processing steps and increasing the yield of platelets available from whole blood donations. Carter BloodCare in Texas was identified as one of the early adopters of this technology to improve manufacturing consistency.
• In March 2024, Cerus Corporation announced positive topline results from its pivotal Phase 3 ReCePI clinical trial evaluating the INTERCEPT Blood System for Red Blood Cells. The study successfully met its primary efficacy endpoint, demonstrating that pathogen-reduced red blood cells were non-inferior to conventional red blood cells when transfused into patients undergoing complex cardiac surgery. The trial also confirmed safety endpoints regarding the incidence of acute kidney injury. These results supported the company's ongoing efforts to seek regulatory approval for pathogen reduction technology in red blood cell transfusions, aiming to enhance the safety of the global blood supply.

Key Market Players

• Pfizer, Inc.
• Bristol-Myers Squibb Company
• Leo Pharma A/S
• Sanofi S.A.
• Xiamen Hisunny Chemical Co., LTD
• AstraZeneca plc
• Baxter International Inc
• Portola Pharmaceuticals, Inc.
• GlaxoSmithKline PLC
• Shandong East Chemical Industry Co.

By Product	By Type	By Application	By Region
Whole Blood Blood Components Blood Derivatives	Platelet Aggregation Inhibitors Fibrinolytics Anticoagulants	Thrombocytosis Pulmonary Embolism Renal Impairment Angina Blood Vessel Complications Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Blood Preparation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Blood Preparation Market, By Product:

• Whole Blood
• Blood Components
• Blood Derivatives

• Blood Preparation Market, By Type:

• Platelet Aggregation Inhibitors
• Fibrinolytics
• Anticoagulants

• Blood Preparation Market, By Application:

• Thrombocytosis
• Pulmonary Embolism
• Renal Impairment
• Angina Blood Vessel Complications
• Others

• Blood Preparation Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE